Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Juni 2017 10:00 ET | Quelle: OxOnc Services Company

OxOnc Announces that Co-development Partner Has Received Approval in Japan and Taiwan for Crizotinib (Xalkori®) as a First-line Treatment for Patients with ROS1-Positive Non-Small Cell Lung Cancer

CAYMAN ISLANDS, June 02, 2017 (GLOBE NEWSWIRE) -- OxOnc Development LP (OxOnc) today announced that co-development partner, Pfizer, Inc., has received regulatory approval in both Japan and Taiwan to...
03. Juni 2016 09:00 ET | Quelle: OxOnc Services Company

Crizotinib Demonstrates Clinical Benefit in Phase II Study of East Asian Patients with ROS1-Positive Non-Small Cell Lung Cancer

CHICAGO, June 03, 2016 (GLOBE NEWSWIRE) -- OxOnc Development LP, (OxOnc), today announced that Study OO-1201, a Phase 2 open-label, single-arm study of crizotinib in East Asian patients with...
08. Februar 2013 10:00 ET | Quelle: OxOnc Services Company

OxOnc Announces Agreement With Pfizer to Develop Crizotinib as First-Line and Second-Line Treatment for Patients With ROS1-Positive Non-Small Cell Lung Cancer

PRINCETON, N.J., Feb. 8, 2013 (GLOBE NEWSWIRE) -- OxOnc Development LP, (OxOnc), today announced that it has entered into a co-development agreement with Pfizer Inc., to conduct a pivotal clinical...